Impact Metrics (as of Dec 2025)

• Technologies personally developed are in 12 active clinical programs (Phase 1–3 + 2 approved products)

• Enabled > $2.8 billion in partner/follow-on financing and acquisition value

• Platforms transferred to 8 different CDMOs across three continents with zero critical CMC 483s

• Mentored 9 scientists who now hold Director/VP roles at flagship gene therapy companies

• Licensed patent families have generated > $75 M in upfront + milestone payments to date

These achievements reflect consistent delivery of breakthroughs that move the entire advanced-therapy field forward — from lab innovation to commercial reality.